Anya Biotech, representing Amsterdam UMC, has won the second edition of the Proefdiervrij Venture Challenge on the 22nd of April 2022. Their winning innovation is based on research from the Department of Medical Biology at the AMC. The team takes home €25.000, – in prize money to kick-start their venture based on human heart models to treat cardiac disease.
The Anya Biotech team, consisting of Harsha Devalla, Marc Roelofs and Sander van Leeuwe, participated in the second edition of the Proefdiervrij Venture Challenge. In this bootcamp program, the participating teams have been guided in the process of translating their scientific breakthrough into a solid business case. This specific version of the Venture Challenge was organised by Proefdiervrij, a foundation idealizing a future without animal testing. The participating teams have brought forward innovations contributing to this cause. In the final, the teams presented in front of an expert jury consisting of Geert-Jan Mulder, Rianne Ellenbroek, Giel Hendriks, Jos Joore and Susan Janssen. The final presentations and subsequent award ceremony took place at Pathé Buitenhof in Den Haag.
The vision of Anya Biotech is to dramatically improve the quality of life of patients suffering from cardiac arrhythmias. They will develop therapies for cardiac arrhythmias such as Atrial Fibrillation and Pacemaker Dysfunction. The cardiac models of Anya Biotech are based on human stem cells, and they mimic the human heart more accurately than the models that are currently used for drug discovery (e.g. animal models). This significantly improves their chances of identifying effective drugs for cardiac arrhythmias, which are currently not effectively treatable.
From Amsterdam UMC also inSteps (location AMC) and Simplexable (location VUmc) participated in the Proefdiervrij Venture Challenge 2022.
Photo credits: Proefdiervrij
The Dutch company NoWa Kitchen presented its newest kitchen featuring only bio-based materials and a sustainable cradle-to-cradle design. A key enabler for the kitchen are plant-based polymers and materials brought to market by the University of Amsterdam’s spin-off company Plantics, stemming from a discovery made by chemists at the Van ‘t Hoff Institute for Molecular […]News
Innoseis recently marked a significant milestone – a decade of pioneering work in seismic sensing. The company, a spin-off of VU and the National Institute for Subatomic Physics, Nikhef, uses precision motion sensing for seismic and guidance applications. We sat down with CEO Mark Beker and CTO Jo van den Brand to learn more about […]News
In the race to a sustainable and healthy future, the benefits of biotech innovations are key. Both biotech academics and entrepreneurs must continue to turn knowledge into social and commercial successes. Nettie Buitelaar, Biotech Booster ‘s CEO, answers five questions in order to tell us how to boost new biotech innovations. The Biotech Booster programme […]News